Table 1.

Drugs demonstrated to be implied in the triggering of the jaw osteonecrosis: name, mode of action or molecular target, and therapeutic indications.

Drugs	Mode of action	Indications
Biphosphonate: SBPs N-BPs	Nonhydrolysable cytotoxic analogs of ATP Farnesyl-diphosphate (FPP) synthase inhibition	Osteoporosis Paget's disease Hypercalcemia of malignancy Tumor-associated osteolysis
Denosumab	Monoclonal antibody that inactivates RANKL	Osteoporosis Tumor-associated osteolysis
Bevacizumab	Monoclonal antibody that inactivates VEGF	Glioblastoma Metastatic cancers: breast, renal, lung, colorectal
Sunitinib, Sorafenib, Cabozantinib	Tyrosine kinase inhibitors that block VEGF receptor	Metastatic cancers: breast, renal, lung, colorectal
Everolimus, Temsirolimus®	mTor inhibitors	Metastatic renal cell carcinoma